cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.19518793
title: Datasets for Reduction of Equatorial Obduction by Atmospheric Intraseasonal Oscillations in the Western and Central Pacific Ocean

description: Abstract: Obduction is the large-scale, irreversible upward water transport from the permanent pycnocline to the surface mixed layer. Using Hybrid Coordinate Ocean Model (HYCOM), this study explores the impact of atmospheric intraseasonal oscillations (ISOs) on the Pacific equatorial obduction that plays a fundamental role in regulating the tropical Pacific climate. Parallel HYCOM experiments forced by atmospheric fields with and without ISO variability are compared to assess the effect of ISOs on the ocean. The results suggest that the ISOs can reduce the annual obduction rate of the western and central equatorial Pacific Ocean (WCEPO; 150°E-160°W, 5°S-5°N) by ~12%, and their impact on the eastern Pacific is rather limited. The ISOs cause prominent intraseasonal variability of mixed layer depth (MLD) in the WCEPO primarily through surface wind forcing, which in turn affect the two key processes controlling the annual obduction rate. First, the intraseasonal MLD deepening events narrow down the total time windows for obduction by ~30% and thereby give rise to the decrease in obduction rate; second, it leads to high-frequency entrainment events and enhances the entrainment rate by ~18%. The increased entrainment rate is overwhelmed by the reduced time windows for effective entrainment, and the net effect of ISOs is to reduce the obduction rate and modify its seasonal cycle. This work highlights the importance of atmospheric ISOs in the equatorial ocean dynamics, with implications for tropical surface temperature and climate variabilities and biogeochemical cycle.
DOI: 10.18746/bmth.data.00000212
title: Dataset for "Microplastic loads within riverine fishes and macroinvertebrates are not predictable from ecological or morphological characteristics"
DOI: 10.6084/m9.figshare.11423841
title: Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus

description: To compare real-world outcomes with newer (insulin glargine 300 U/mL; Gla-300) versus standard of care (SoC) basal insulins (BIs) in the REACH (insulin-naïve; NCT02967224) and REGAIN (basal insulin-treated; NCT02967211) studies in participants with uncontrolled type 2 diabetes (T2DM) in Europe and Brazil. In these open-label, parallel-group, pragmatic studies, patients (HbA<sub>1c</sub> &gt; 7.0%) were randomized to Gla-300 or SoC BI for a 6-month treatment period (to demonstrate non-inferiority of Gla-300 vs SoC BIs for HbA<sub>1c</sub> change [non-inferiority margin 0.3%]) and a 6-month extension period (continuing with their assigned treatment). Insulin titration/other medication changes were at investigator/patient discretion post-randomization. Overall, 703 patients were randomized to treatment in REACH (Gla-300, <i>n</i> = 352; SoC, <i>n</i> = 351) and 609 (Gla-300, <i>n</i> = 305, SoC, <i>n</i> = 304) in REGAIN. The primary outcome, non-inferiority of Gla-300 versus SoC for HbA<sub>1c</sub> change from baseline to month 6, was met in REACH (least squares [LS] mean difference 0.12% [95% CI –0.046 to 0.281]) but not REGAIN (LS mean difference 0.17% [0.015–0.329]); no between-treatment difference in HbA<sub>1c</sub> change was shown after 12 months in either study. BI dose increased minimally from baseline to 12 months in REACH (Gla-300, +0.17 U/kg; SoC, +0.15 U/kg) and REGAIN (Gla-300, +0.11 U/kg; SoC, +0.07 U/kg). Hypoglycemia incidence was low and similar between treatment arms in both studies. In both REACH and REGAIN, no differences in glycemic control or hypoglycemia outcomes with Gla-300 versus SoC BIs were seen over 12 months. However, the suboptimal insulin titration in REACH and REGAIN limits comparisons of outcomes between treatment arms and suggests that more titration instruction/support may be required for patients to fully derive the benefits from newer basal insulin formulations.
DOI: 10.6084/m9.figshare.11423841.v2
title: Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus

description: To compare real-world outcomes with newer (insulin glargine 300 U/mL; Gla-300) versus standard of care (SoC) basal insulins (BIs) in the REACH (insulin-naïve; NCT02967224) and REGAIN (basal insulin-treated; NCT02967211) studies in participants with uncontrolled type 2 diabetes (T2DM) in Europe and Brazil. In these open-label, parallel-group, pragmatic studies, patients (HbA<sub>1c</sub> &gt; 7.0%) were randomized to Gla-300 or SoC BI for a 6-month treatment period (to demonstrate non-inferiority of Gla-300 vs SoC BIs for HbA<sub>1c</sub> change [non-inferiority margin 0.3%]) and a 6-month extension period (continuing with their assigned treatment). Insulin titration/other medication changes were at investigator/patient discretion post-randomization. Overall, 703 patients were randomized to treatment in REACH (Gla-300, <i>n</i> = 352; SoC, <i>n</i> = 351) and 609 (Gla-300, <i>n</i> = 305, SoC, <i>n</i> = 304) in REGAIN. The primary outcome, non-inferiority of Gla-300 versus SoC for HbA<sub>1c</sub> change from baseline to month 6, was met in REACH (least squares [LS] mean difference 0.12% [95% CI –0.046 to 0.281]) but not REGAIN (LS mean difference 0.17% [0.015–0.329]); no between-treatment difference in HbA<sub>1c</sub> change was shown after 12 months in either study. BI dose increased minimally from baseline to 12 months in REACH (Gla-300, +0.17 U/kg; SoC, +0.15 U/kg) and REGAIN (Gla-300, +0.11 U/kg; SoC, +0.07 U/kg). Hypoglycemia incidence was low and similar between treatment arms in both studies. In both REACH and REGAIN, no differences in glycemic control or hypoglycemia outcomes with Gla-300 versus SoC BIs were seen over 12 months. However, the suboptimal insulin titration in REACH and REGAIN limits comparisons of outcomes between treatment arms and suggests that more titration instruction/support may be required for patients to fully derive the benefits from newer basal insulin formulations.
DOI: 10.6084/m9.figshare.11423841.v1
title: Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus

description: <b><i>Objective:</i></b> To compare real-world outcomes with newer (insulin glargine 300 U/mL; Gla-300) versus standard of care (SoC) basal insulins (BIs) in the REACH (insulin-naïve; NCT02967224) and REGAIN (basal insulin-treated; NCT02967211) studies in participants with uncontrolled type 2 diabetes (T2DM) in Europe and Brazil. <b><i>Methods:</i></b> In these open-label, parallel-group, pragmatic studies, patients (HbA<sub>1c</sub> &gt;7.0%) were randomized to Gla-300 or SoC BI for a 6-month treatment period (to demonstrate non-inferiority of Gla-300 vs SoC BIs for HbA<sub>1c</sub> change [non-inferiority margin 0.3%]) and a 6-month extension period (continuing with their assigned treatment). Insulin titration/other medication changes were at investigator/patient discretion post-randomization. <b><i>Results:</i></b> Overall, 703 patients were randomized to treatment in REACH (Gla-300, n = 352; SoC, n = 351) and 609 (Gla-300 n = 305, SoC n = 304) in REGAIN. The primary outcome, non-inferiority of Gla-300 versus SoC for HbA<sub>1c</sub> change from baseline to Month 6, was met in REACH (least squares [LS] mean difference 0.12% [95% CI –0.046 to 0.281]) but not REGAIN (LS mean difference 0.17% [0.015 to 0.329]); no between-treatment difference in HbA<sub>1c</sub> change was shown after 12 months in either study. BI dose increased minimally from baseline to 12 months in REACH (Gla-300, +0.17 U/kg; SoC; +0.15 U/kg) and REGAIN (Gla-300, +0.11 U/kg; SoC, +0.07 U/kg). Hypoglycemia incidence was low and similar between treatment arms in both studies. <b><i>Conclusion:</i></b> In both REACH and REGAIN, no differences in glycemic control or hypoglycemia outcomes with Gla-300 versus SoC BIs was seen over 12 months. However, the suboptimal insulin titration in REACH and REGAIN limits comparisons of outcomes between treatment arms and suggests that more titration instruction/support may be required for patients to fully derive the benefits from newer basal insulin formulations.
DOI: 10.6084/m9.figshare.1604878
title: Developing a tool to measure pharmacoeconomic outcomes of post-surgical pain management interventions

description: Financial pressures have limited the ability of providers to use medication that may improve clinical outcomes and patient satisfaction. New interventions are often fraught with resistance from individual cost centers. A value realization tool (VRT) is essential for separate cost centers to communicate and comprehend the overall financial and clinical implications of post-surgical pain management medication interventions (PSMI). The goal was to describe development of a VRT. An evaluation of common in-patient PSMI approaches, impacts, and costs was performed. A multidisciplinary task force guided development of the VRT to ensure appropriate representation and relevance to clinical practice. The main outcome was an Excel-based tool that communicates the overall cost/benefit of PSMI for the post-operative patient encounter. The VRT aggregated input data on costs, clinical impact, and nursing burden of PSMI assessment and monitoring into two high-level outcome reports: Overall Cost Impact and Nurse & Patient Impact. Costs included PSMI specific medication, equipment, professional placement, labor, overall/opioid-related adverse events, re-admissions, and length of stay. Nursing impact included level of practice interference, job satisfaction, and patient care metrics. Patient impact included pain scores, opioid use, PACU time, and satisfaction. Reference data was provided for individual institutions that may not collect all variables included in the VRT. The VRT is a valuable way for administrators to assess PSMI cost/benefits and for individual cost centers to see the overall value of individual interventions. The user-friendly, decision-support tool allows the end-user to use built-in referenced or personalized outcome data, increasing relevance to their institutions. This broad picture could facilitate communication across cost centers and evidence-based decisions for appropriate use and impacts of PSMI.
DOI: 10.6084/m9.figshare.1604878.v2
title: Developing a tool to measure pharmacoeconomic outcomes of post-surgical pain management interventions

description: Financial pressures have limited the ability of providers to use medication that may improve clinical outcomes and patient satisfaction. New interventions are often fraught with resistance from individual cost centers. A value realization tool (VRT) is essential for separate cost centers to communicate and comprehend the overall financial and clinical implications of post-surgical pain management medication interventions (PSMI). The goal was to describe development of a VRT. An evaluation of common in-patient PSMI approaches, impacts, and costs was performed. A multidisciplinary task force guided development of the VRT to ensure appropriate representation and relevance to clinical practice. The main outcome was an Excel-based tool that communicates the overall cost/benefit of PSMI for the post-operative patient encounter. The VRT aggregated input data on costs, clinical impact, and nursing burden of PSMI assessment and monitoring into two high-level outcome reports: Overall Cost Impact and Nurse & Patient Impact. Costs included PSMI specific medication, equipment, professional placement, labor, overall/opioid-related adverse events, re-admissions, and length of stay. Nursing impact included level of practice interference, job satisfaction, and patient care metrics. Patient impact included pain scores, opioid use, PACU time, and satisfaction. Reference data was provided for individual institutions that may not collect all variables included in the VRT. The VRT is a valuable way for administrators to assess PSMI cost/benefits and for individual cost centers to see the overall value of individual interventions. The user-friendly, decision-support tool allows the end-user to use built-in referenced or personalized outcome data, increasing relevance to their institutions. This broad picture could facilitate communication across cost centers and evidence-based decisions for appropriate use and impacts of PSMI.
DOI: 10.6084/m9.figshare.1604878.v1
title: Developing a tool to measure pharmacoeconomic outcomes of post-surgical pain management interventions

description: <b>Background:</b>Financial pressures have limited the ability of providers to use medication that may improve clinical outcomes and patient satisfaction. New interventions are often fraught with resistance from individual cost centers. A value realization tool (VRT) is essential for separate cost centers to communicate and comprehend the overall financial and clinical implications of post-surgical pain management medication interventions (PSMI). The goal was to describe development of a VRT.<b>Methods:</b>An evaluation of common in-patient PSMI approaches, impacts, and costs was performed. A multidisciplinary task force guided development of the VRT to ensure appropriate representation and relevance to clinical practice. The main outcome was an Excel-based tool that communicates the overall cost/benefit of PSMI for the post-operative patient encounter.<b>Results:</b>The VRT aggregated input data on costs, clinical impact, and nursing burden of PSMI assessment and monitoring into two high-level outcome reports: Overall Cost Impact and Nurse & Patient Impact. Costs included PSMI specific medication, equipment, professional placement, labor, overall/opioid-related adverse events, re-admissions, and length of stay. Nursing impact included level of practice interference, job satisfaction, and patient care metrics. Patient impact included pain scores, opioid use, PACU time, and satisfaction. Reference data was provided for individual institutions that may not collect all variables included in the VRT.<b>Conclusions:</b>The VRT is a valuable way for administrators to assess PSMI cost/benefits and for individual cost centers to see the overall value of individual interventions. The user-friendly, decision-support tool allows the end-user to use built-in referenced or personalized outcome data, increasing relevance to their institutions. This broad picture could facilitate communication across cost centers and evidence-based decisions for appropriate use and impacts of PSMI.
DOI: 10.4121/13517384
title: Supporting data for the publication: Rapidly migrating secondary bedforms can persist on the lee of slowly migrating primary river dunes

description: <i>The dataset contains supporting data for the publication Rapidly migrating secondary bedforms can persist in the lee of slowly migrating primary river dunes (2020), Zomer et al.</i><i>The dataset includes ADCP data (including GPS and heading data) and bathymetric data interpolated on an equidistant grid with a horizontal resolution of 0.1m and a vertical resolution of 0.01m. </i><i>The data was acquired on October 11, 2018 in the river Waal. </i>
DOI: 10.4121/13517384.v3
title: Supporting data for the publication: Rapidly migrating secondary bedforms can persist on the lee of slowly migrating primary river dunes

description: <i>The dataset contains supporting data for the publication Rapidly migrating secondary bedforms can persist in the lee of slowly migrating primary river dunes (2020), Zomer et al.</i><i>The dataset includes ADCP data (including GPS and heading data) and bathymetric data interpolated on an equidistant grid with a horizontal resolution of 0.1m and a vertical resolution of 0.01m. </i><i>The data was acquired on October 11, 2018 in the river Waal. </i>
DOI: 10.4121/13517384.v2
title: Supporting data for the publication: Rapidly migrating secondary bedforms can persist on the lee of slowly migrating primary river dunes

description: <i>The dataset contains supporting data for the publication Rapidly migrating secondary bedforms can persist in the lee of slowly migrating primary river dunes (2020), Zomer et al.</i><i>The dataset includes ADCP data (including GPS and heading data) and bathymetric data interpolated on an equidistant grid with a horizontal resolution of 0.1m and a vertical resolution of 0.01m. </i><i>The data was acquired on October 11, 2018 in the river Waal. </i>
DOI: 10.6084/m9.figshare.19524451
title: Data_erectile dysfunction_Tabora_Figshare.xlsx

description: The dataset represent a total of 34 medicinal plants used by traditional healers to manage erectile dysfunction in Tabora region.<br>The ethnobotanical data were collected using a semi structured questionnaire. During the survey names of plants, parts used, sources, methods of preparation and administration were documented. There after data were analyzed by computing percentage frequencies and familiarity index. <br><br>Basically the findings informs that there is a need to conduct an ethno-pharmacological, toxicological and phytochemical studies of the documented plant species for discovery of modern drugs.<br><br>
DOI: 10.6084/m9.figshare.19524451.v1
title: Data_erectile dysfunction_Tabora_Figshare.xlsx

description: The dataset represent a total of 34 medicinal plants used by traditional healers to manage erectile dysfunction in Tabora region.<br>The ethnobotanical data were collected using a semi structured questionnaire. During the survey names of plants, parts used, sources, methods of preparation and administration were documented. There after data were analyzed by computing percentage frequencies and familiarity index. <br><br>Basically the findings informs that there is a need to conduct an ethno-pharmacological, toxicological and phytochemical studies of the documented plant species for discovery of modern drugs.<br><br>
DOI: 10.25493/fke3-y2
title: Density measurements of different receptors for CA1 (Hippocampus) [human]

description: This dataset contains the densities (in fmol/mg protein) of receptors for classical neurotransmitters in CA1 (Hippocampus) obtained by means of quantitative _in vitro_ autoradiography. The receptor densities are visualized as _fingerprints_ (**fp**), which provide the mean density and standard deviation for each of the analyzed receptor types, averaged across samples. Information on the used tissue samples and corresponding subjects, as well as analyzed receptors accompanies the provided dataset.
DOI: 10.6084/m9.figshare.19418993
title: Supplemental Tables from Mutualism has its limits: consequences of asymmetric interactions between a well-defended plant and its herbivorous pollinator

description: Additional tables provide data concerning plant accessions, leaf disk-larval assays, clip-cage larval assays, whole plant larval growth, comparative larval performance, volatile identification, volatile emission rates and phenolic (non volatile) compound data from <i>Oenothera harringtonii</i>.
DOI: 10.6084/m9.figshare.19418993.v1
title: Supplemental Tables from Mutualism has its limits: consequences of asymmetric interactions between a well-defended plant and its herbivorous pollinator

description: Additional tables provide data concerning plant accessions, leaf disk-larval assays, clip-cage larval assays, whole plant larval growth, comparative larval performance, volatile identification, volatile emission rates and phenolic (non volatile) compound data from <i>Oenothera harringtonii</i>.
DOI: 10.15151/esrf-es-686690783
title: Cryo-electron microscopy EPN BAG

description: At the EPN campus level structural biology work is carried out in all the 4 institutes (IBS, ESRF, ILL and EMBL). Today all structural biology groups are turning to cryo-EM. The EM demand is therefore extremely high and present in the 4 Institutes. In a nutshell, there are 42 PIs that could benefit from Krios time on the EPN campus (more than 90 different samples). Around 20 % of the sample are ready for high resolution data collection with already prepared grids that have been pre-screened on Glacios microscopes. Whereas some work could be carried out on Glacios microscopes, for difficult samples the use of a krios is indispensable (heterogeneous sample or limited concentration requiring a large number of images; small protein etc). Only these samples will be selected for Krios time at the BAG level.
DOI: 10.5281/zenodo.6414075
title: CNN-Filter-DB-Robust

description: Dataset for the Paper "Adversarial Robustness through the Lens of Convolutional Filters". <strong>More details:</strong> https://github.com/paulgavrikov/cvpr22w_RobustnessThroughTheLens
description: This work was supported in part by the German Ministry for Science, Research and Arts Baden-Wuerttemberg (MWK) under Grant 32-7545.20/45/1 Quality Assurance of Machine Learning Applications (Q-AMeLiA). https://q-amelia.in.hs-furtwangen.de/
DOI: 10.5281/zenodo.6414074
title: CNN-Filter-DB-Robust

description: Dataset for the Paper "Adversarial Robustness through the Lens of Convolutional Filters". <strong>More details:</strong> https://github.com/paulgavrikov/cvpr22w_RobustnessThroughTheLens
description: This work was supported in part by the German Ministry for Science, Research and Arts Baden-Wuerttemberg (MWK) under Grant 32-7545.20/45/1 Quality Assurance of Machine Learning Applications (Q-AMeLiA). https://q-amelia.in.hs-furtwangen.de/
DOI: 10.5281/zenodo.6416858
title: A protective HLA extended haplotype outweighs the major COVID-19 risk factor inherited from Neanderthals in the Sardinian population

description: Sardinia has one of the lowest incidences of hospitalization and related mortality in Europe. In this dataset we reported 358 patients with COVID-19, in which we evaluated the frequency of the Neanderthal risk locus variant on chromosome 3 (rs35044562), considered to be a major risk factor for a severe SARS-CoV-2 disease course.
DOI: 10.5281/zenodo.6416857
title: A protective HLA extended haplotype outweighs the major COVID-19 risk factor inherited from Neanderthals in the Sardinian population

description: Sardinia has one of the lowest incidences of hospitalization and related mortality in Europe. In this dataset we reported 358 patients with COVID-19, in which we evaluated the frequency of the Neanderthal risk locus variant on chromosome 3 (rs35044562), considered to be a major risk factor for a severe SARS-CoV-2 disease course.
DOI: 10.6084/m9.figshare.18851015
title: Data repository_Lim et al_Com Biol.xlsx

description: This data set was prepared for the manuscript, "<b>Bioconversion of CO to formate by artificially designed carbon monoxide:formate oxidoreductase in hyperthermophilic archaea,</b>" submitted to Communications Biology.
DOI: 10.6084/m9.figshare.18851015.v3
title: Data repository_Lim et al_Com Biol.xlsx

description: This data set was prepared for the manuscript, "<b>Bioconversion of CO to formate by artificially designed carbon monoxide:formate oxidoreductase in hyperthermophilic archaea,</b>" submitted to Communications Biology.
DOI: 10.6084/m9.figshare.18851015.v2
title: Data repository_Lim et al_Com Biol.xlsx

description: This data set was prepared for the manuscript, "<b>Bioconversion of CO to formate by artificially designed carbon monoxide:formate oxidoreductase in hyperthermophilic archaea,</b>" submitted to Communications Biology.
DOI: 10.6084/m9.figshare.19149513
title: Electronic Supplementary Material 2.xlsx from Finite-element and semi-analytical study of elastic wave propagation in strongly scattering polycrystals

description: The simulation results presented in this work
DOI: 10.6084/m9.figshare.19149513.v1
title: Electronic Supplementary Material 2.xlsx from Finite-element and semi-analytical study of elastic wave propagation in strongly scattering polycrystals

description: The simulation results presented in this work